Roche Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Unlock the Full Value Chain Analysis for Deeper Insight
This Roche Value Chain Analysis helps you understand how Roche creates value across its support and primary activities in a clear, structured format. This page already shows a real preview of the analysis, so you can review the style and substance before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
Roche's firm infrastructure must run Pharmaceuticals and Diagnostics under one governance, compliance, and enterprise risk system. That matters across more than 100 countries, where the same controls shape capital allocation, pricing discipline, and post-market surveillance. In 2025, that setup was key to managing a group with CHF 60.8 billion in 2024 sales and a complex global regulatory load.
Human Resource Management
In 2025, Roche's talent base spans over 100,000 employees, and its human resource management must recruit scientists, clinical developers, regulatory specialists, manufacturing experts, and diagnostics engineers. Targeted hiring and training help keep GMP discipline, clinical quality, and drug-diagnostics teamwork tight. This matters in a group that spent CHF 13.2 billion on R&D in 2024, so skilled people are a core value-chain input.
Technology Development
Roche's technology development is the engine of its value chain: in 2025, Roche spent about CHF 13.2 billion on R&D to advance oncology, immunology, infectious diseases, ophthalmology, neuroscience, and diagnostics. That spend supports biologics, assays, and data-enabled platforms that sharpen precision medicine and speed product upgrades. In a business that generated roughly CHF 60 billion in annual sales, this keeps Roche's innovation base central to growth and margin defense.
Procurement
Roche sources APIs, biologic raw materials, reagents, lab consumables, packaging, and specialized equipment from a global supplier base. Its procurement team screens and qualifies suppliers, then keeps tight quality oversight to protect continuity for temperature-sensitive inputs and regulated manufacturing.
This matters because even small supply breaks can halt batch release, so Roche uses dual sourcing, traceability, and cold-chain controls to reduce risk across its pharma and diagnostics lines.
Roche's support engine powers a CHF 60.8B global pharma-diagnostics model
Roche's support activities keep a global pharma-diagnostics model running. In 2025, its 100,000+ staff, CHF 13.2 billion R&D base, and strict supplier controls supported quality, compliance, and fast product updates. Its 2024 sales of CHF 60.8 billion show how much this backbone has to protect.
| Support activity | 2025 signal |
|---|---|
| HR, tech, procurement | 100,000+ staff; CHF 13.2bn R&D |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Roche's inbound logistics depend on tightly controlled biologic starting materials, chemical compounds, reagents, and packaging for medicines and diagnostics. In the latest annual reporting cycle, Roche generated CHF 60.5 billion in sales, so even small supplier or cold-chain failures can hit output at scale. Strong traceability, cold-chain handling, and supplier quality checks help Roche cut contamination risk, avoid shortages, and keep regulated supply lines moving.
Operations
Roche turns R&D into products through drug development, biologics manufacturing, diagnostics kit output, and quality control. Its operating model has to serve 2 regulated engines, Pharma and Diagnostics, plus integrated diabetes care. That means sterile biomanufacturing, tissue testing, and device assembly all run under one global quality system.
Outbound Logistics
Roche's outbound logistics moves prescription medicines, diagnostic instruments, and consumables through regulated global channels, so on-time delivery and cold-chain control are critical. In 2025, this side of the value chain still had to serve hospitals, laboratories, pharmacies, and distributors with strict traceability and product integrity. Any delay can hit patient care, and any breach can stop shipments at customs or by regulators.
Marketing and Sales
Roche sells to physicians, payers, hospitals, laboratories, and health systems with clinical evidence, medical affairs, and market access teams. In diagnostics, it often bundles instruments, reagents, and service contracts, which lifts recurring revenue and locks in the installed base.
This is a high-touch sales model, so proof of outcomes matters more than price. Roche's 2025 commercial focus stayed on premium science-backed products that can win reimbursement and drive repeat use across large care networks.
Service
Roche's service arm keeps diagnostics and diabetes systems running with maintenance, technical support, software updates, reagent replenishment, and pharmacovigilance. In 2025, that post-sale work matters because uptime and assay accuracy shape lab throughput and clinical trust. For connected platforms, fast training and issue resolution help protect recurring revenue and customer retention.
Roche's 2025 Scale: CHF 60.5B in Pharma and Diagnostics
Roche's primary activities in 2025 were built around high-value pharma and diagnostics operations: regulated biomanufacturing, kit and instrument production, global distribution, and service support. With CHF 60.5 billion in sales, execution quality mattered at scale, especially for cold-chain products and installed-base diagnostics. Commercially, Roche relies on evidence-led selling, reimbursement access, and recurring reagent demand.
| 2025 data | Value |
|---|---|
| Sales | CHF 60.5 billion |
| Core engines | Pharma, Diagnostics |
| Primary sales model | Evidence-led, high-touch |
Preview Before You Purchase
Roche Reference Sources
This is the actual Roche Value Chain Analysis document you'll receive upon purchase – no surprises, just professional quality. The preview below is taken directly from the full report, so what you see is exactly what you get. Purchase unlocks the complete, in-depth version immediately after checkout.
Frequently Asked Questions
Roche's R&D and regulatory infrastructure supports the whole value chain. The company spans 2 core businesses-Pharmaceuticals and Diagnostics-and the source material highlights 5 therapeutic areas: oncology, immunology, infectious diseases, ophthalmology, and neuroscience. That breadth links discovery, approval, manufacturing, and monitoring into one operating system across drug and diagnostic workflows.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.